Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on April 28, 2004, to report its financial results for the first quarter of 2004. The filing incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) that detail the company's operational performance and financial condition for the period. This report serves as the primary disclosure vehicle for these key quarterly financial updates, providing investors with essential data to assess the company's performance and outlook.
Key Highlights
- 1BMY announced its first quarter 2004 financial results via an 8-K filing.
- 2The filing includes a press release dated April 28, 2004, detailing the company's Q1 2004 earnings.
- 3Supplemental financial information not included in the press release is also provided as Exhibit 99.2.
- 4The report is filed under Items 9 (Regulation FD Disclosure) and 12 (Results of Operations and Financial Condition).
- 5Investors can refer to Exhibits 99.1 and 99.2 for a comprehensive understanding of BMY's Q1 2004 performance.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce and provide access to Bristol-Myers Squibb's financial results for the first quarter of 2004, in compliance with SEC regulations, particularly Regulation FD.
The detailed financial results and supplemental information for Q1 2004 are provided in Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental information) which are incorporated by reference into this 8-K filing.
The press release (Exhibit 99.1) typically contains key financial metrics such as revenue, net income, earnings per share, and commentary on performance drivers. The supplemental information (Exhibit 99.2) may offer more granular data or additional context not covered in the main press release.